Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(STAR-02)

NCT06766578 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT06766578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06766578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(STAR-02)
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 30, 2024
Completion date
December 31, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric/gastroesophageal junction adenocarcinoma